GWP
TVTX icon

Gen-Wealth Partners’s Travere Therapeutics TVTX Stock Holding History

Gen-Wealth Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,210
Closed -$75.4K – 663
2025
Q1 		$75.4K Hold
4,210
– – 0.03% 303
2024
Q4 		$73.3K Buy
+4,210
New +$74.5K 0.03% 326

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gen-Wealth Partners's TVTX Position: Q2 2025 in Review

Gen-Wealth Partners sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 4,210 shares — an estimated $75.4K sold.

Gen-Wealth Partners first reported a position in TVTX in Q4 2024 and held it in 2 quarters. The position peaked at $75.4K in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Gen-Wealth Partners reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Gen-Wealth Partners sold 4,210 Travere Therapeutics shares in Q2 2025, an estimated $75.4K.
  • Gen-Wealth Partners first reported a position in Travere Therapeutics in Q4 2024 and held it in 2 quarters.
  • Gen-Wealth Partners's Travere Therapeutics position peaked at $75.4K in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Gen-Wealth Partners's 13F filing for Q2 2025, filed 14 Aug 2025.